Arcturus Therapeutics Ltd (ARCT)

$10.53 +0.23 (2.23%)
Market Cap 286.66M
Revenue (ttm) 152.31M
Net Income (ttm) -80.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -53.14%
Debt to Equity Ratio 0.00
Volume 358,100
Avg Vol 441,776
Day's Range N/A - N/A
Shares Out 27.12M
Stochastic %K 84%
Beta 3.41
Analysts Strong Sell
Price Target $64.75

Latest News on ARCT

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Apr 10, 2025, 8:00 AM EDT - 8 days ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 9:44 PM EST - 6 weeks ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 6, 2025, 4:01 PM EST - 6 weeks ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Mar 5, 2025, 4:30 PM EST - 6 weeks ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 24, 2025, 4:01 PM EST - 7 weeks ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 14, 2025, 8:30 AM EST - 2 months ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Feb 4, 2025, 8:30 AM EST - 2 months ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 31, 2025, 3:00 AM EST - 2 months ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 30, 2025, 4:01 PM EST - 2 months ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 10, 2025, 8:00 AM EST - 3 months ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Jan 6, 2025, 4:01 PM EST - 3 months ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 4:01 PM EST - 4 months ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Nov 26, 2024, 4:01 PM EST - 5 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 5 months ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:44 PM EST - 5 months ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 14, 2024, 1:00 AM EST - 5 months ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 11, 2024, 4:01 PM EST - 5 months ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 11:24 PM EST - 5 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Nov 7, 2024, 4:01 PM EST - 5 months ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Oct 31, 2024, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 30, 2024, 8:00 AM EDT - 7 months ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 13, 2024, 8:15 AM EDT - 7 months ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Sep 3, 2024, 8:30 AM EDT - 8 months ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 27, 2024, 5:00 PM EDT - 8 months ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 9, 2024, 5:27 AM EDT - 9 months ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 8:50 PM EDT - 9 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 5, 2024, 4:01 PM EDT - 9 months ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Aug 1, 2024, 4:01 PM EDT - 9 months ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 18, 2024, 7:30 PM EDT - 9 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jul 1, 2024, 4:01 PM EDT - 10 months ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 20, 2024, 8:00 AM EDT - 10 months ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Arcturus: A Hidden Gem In The Biotech Sector

Jun 8, 2024, 2:42 AM EDT - 11 months ago

Arcturus: A Hidden Gem In The Biotech Sector

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Jun 7, 2024, 10:30 AM EDT - 11 months ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 28, 2024, 6:30 AM EDT - 11 months ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 20, 2024, 8:30 AM EDT - 11 months ago

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

May 8, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Apr 25, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Apr 23, 2024, 6:01 AM EDT - 1 year ago

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 6:32 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Mar 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Feb 26, 2024, 9:00 AM EST - 1 year ago

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

Feb 22, 2024, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

Feb 20, 2024, 9:00 AM EST - 1 year ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

Feb 5, 2024, 8:30 AM EST - 1 year ago

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments

Feb 2, 2024, 11:25 AM EST - 1 year ago

Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments

Arcturus: H1 2024 Rare Disease Drug Data On Deck

Jan 31, 2024, 5:20 PM EST - 1 year ago

Arcturus: H1 2024 Rare Disease Drug Data On Deck

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Dec 21, 2023, 8:00 AM EST - 1 year ago

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 8:30 AM EST - 1 year ago

Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

Nov 28, 2023, 8:05 AM EST - 1 year ago

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults

Nov 28, 2023, 8:00 AM EST - 1 year ago

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults